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Transforming growth factor-b (TGF-b) has been
shown to be required for Th17 cell differentiation
via Smad-independent mechanisms. The molecular
mechanism underlying this pathway remains to be
clarified, however. We searched for genes regulated
by TGF-b through the Smad-independent pathway
by using Smad2 and Smad3 double-deficient
T cells and identified the transcription factor Eome-
sodermin (Eomes), whose expression was sup-
pressed by TGF-b via the c-Jun N-terminal kinase
(JNK)-c-Jun signaling pathway. Inhibition of JNK
strongly suppressed disease in an in vivo EAE model
aswell as in vitro Th17 cell induction. Overexpression
of Eomes substantially suppressed Th17 cell differ-
entiation, whereas ablation of Eomes expression
could substitute for TGF-b in Th17 cell induction in
primary T cells. Eomes suppressed Rorc and Il17a
promoters by directly binding to the proximal region
of these promoters. In conclusion, the suppression
of Eomes by TGF-b via the JNK pathway is an impor-
tant mechanism for Smad-independent Th17 cell
differentiation.
INTRODUCTION
CD4+ T helper (Th) cells play a central role in the immune
response. Upon activation by antigens, Th cells follow distinct
developmental pathways, through which they develop special-
ized properties and effector functions. CD4+ T cells were tradi-
tionally thought to differentiate into two subsets: Th1 cells and
Th2 cells (Mosmann and Coffman, 1989). Th1 cells require the
transcription factor T-bet, secrete IFN-g, and regulate cellular
immunity. Th2 cells, in contrast, express GATA3 and c-Maf;
produce IL-4, IL-5, and IL-13; and mediate humoral responses
(Abbas et al., 1996; Flavell, 1999; Murphy and Reiner, 2002).
Recently, however, an additional subset of Th cells has been
identified; these are the Th17 cells, characterized by the produc-
tion of IL-17A. They play an important role in autoimmune
diseases, elimination of extracellular bacteria, and cancer (Aujlaet al., 2007; Kikly et al., 2006; Kottke et al., 2007). The differenti-
ation of Th17 cells from naive T cells requires TGF-b and IL-6,
both in vitro and in vivo (Bettelli et al., 2006; Mangan et al.,
2006; Veldhoen et al., 2006; Yoshimura et al., 2010). TGF-b
and IL-6 induce the nuclear orphan receptors RORgt and
RORa, which have also been shown to be indispensable for
the differentiation of Th17 cells (Ivanov et al., 2006; Yang et al.,
2008b). In addition, both IL-21 and IL-23 are thought to be critical
for the maturation and/or maintenance of Th17 cells (Korn et al.,
2007; McKenzie et al., 2006; Nurieva et al., 2007).
The major signaling pathway of TGF-b is the Smad pathway.
TGF-b receptor activates Smad transcription factors, including
three structurally similar proteins: Smad2 and Smad3
(receptor-associated Smads) and Smad4. Smad2 or Smad3
are directly phosphorylated and activated by TGF-bR and heter-
odimerize with Smad4 or TIF1g (Yoshimura andMuto, 2011). The
activated Smad complex translocates into the nucleus and
regulates the transcription of target genes. However, we and
others have demonstrated through experiments with Smad4-
deficient or Smad2 and Smad3 double-deficient T cells that
Rorc induction by TGF-b is independent of the Smad signaling
pathway (Takimoto et al., 2010; Yang et al., 2008a). Smad-inde-
pendent TGF-b signaling occurs through various pathways now
being discovered, including the Ras-extracellular signal-regu-
lated kinase (Erk), TGF-b-activated kinase-mitogen-activated
protein kinase (MAPK) kinase 4-c-Jun N-terminal kinase (TAK-
MKK4-JNK), TAK-MKK3/6-p38, Rho-Rac-cdc42 MAPK, and
phosphatidylinositol 3-kinase (PI3K)-Akt pathways (Yoshimura
et al., 2010). The pathway for RORgt induction, however,
remained to be clarified prior to the present study.
Th17 cell differentiation is regulated by various transcription
factors, including, for example, aryl hydrocarbon receptor
(AHR) and interferon regulatory factor 4 (IRF4), which positively
regulate Th17 cell development (Huber et al., 2008; Kimura
et al., 2008), and the retinoic acid receptor RAR-RXR as well
as Ets1, which negatively regulate Th17 cell differentiation
(Moisan et al., 2007; Mucida et al., 2007). It has recently been
demonstrated that Batf and IkBd are crucial for Th17 cell devel-
opment (Okamoto et al., 2010; Schraml et al., 2009). Further-
more, we and others have also reported that Foxp3 inhibits
Il17a expression through interaction with RORgt (Ichiyama
et al., 2008; Zhou et al., 2008) and that growth factor-indepen-
dent 1 (Gfi1) negatively regulates Th17 cell differentiation by in-
hibiting RORgt activity (Ichiyama et al., 2009; Zhu et al., 2009).Immunity 34, 741–754, May 27, 2011 ª2011 Elsevier Inc. 741
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independent signals of TGF-b.
By using a microarray analysis, we identified Eomes as a gene
that is Smad independently regulated by TGF-b in naive T cells
(Takimoto et al., 2010). Eomesodermin (Eomes) is a T-box factor
that plays a key regulatory role in initiating mesodermal cell fate
in most vertebrates and has an additional role in mammalian
trophoblast differentiation (Ryan et al., 1996). It has been shown
that the T-box domain of Eomes has high similarity to that of
T-bet (Yi et al., 1999) and that Eomes regulates IFN-g production
in NK and CD8 T cells (Pearce et al., 2003). Eomes expression is
upregulated after TCR stimulation in CD4+ T cells and has been
shown to be involved in IL-21-mediated IFN-g regulation (Suto
et al., 2006). The role of Eomes in CD4+ effector T cell develop-
ment remains to be determined.
In this study, we first found that the expression of Eomes was
substantially downregulated via a Smad-independent mecha-
nism activated by TGF-b. We established that the TGF-b-JNK-
c-Jun signaling pathway strongly depressed Eomes expression
and that repression of Eomes was necessary for Th17 cell induc-
tion and could replace part of the action of TGF-b. We also
showed that Eomes directly binds to the promoter of Th17
cell-related genes such as Rorc and Il17a and inhibits their tran-
scription. All in all, our study identified an important pathway for
Th17 cell differentiation driven by TGF-b.
RESULTS
Identification of Eomes as a Smad Independently
Regulated Gene Related to Th17 Cell Differentiation
We have previously reported that TGF-b-mediated Rorc induc-
tion occurs normally in Smad2/Smad3/ CD4+ T cells. We
compared mRNA gene profiles regulated by TGF-b by using
WT and Smad2/Smad3/ T cells (Takimoto et al., 2010).
Genes that were upregulated more than 4-fold in a Smad-inde-
pendent manner included Rorc, Ccr8, Socs2, Gja, and Ikzf4.
Eomes and Wisp1 were downregulated to amounts that were
less than 25% of controls by TGF-b, also via a Smad-indepen-
dent mechanism. We cloned these Smad-independent genes
into retrovirus vectors and examined the effect of overexpres-
sion of these genes and found that only Eomes strongly affected
Th17 cell differentiation (data not shown).
Recently, it has been shown that CD8+ T cells lacking both
T-bet and Eomes become IL-17-producing CD8+ T cells (Tc17)
in LCMV infection (Pearce et al., 2003). Eomes has also been
shown to play a critical role in directing T cell differentiation to
Th1 rather than Th17 cells (Yang et al., 2008c). Therefore, we
focused on Eomes to clarify the Smad-independent pathway
of TGF-b signaling in T cells.
First, we confirmed that the expression of Eomes can be regu-
lated by TGF-b in CD4+ T cells by immunoblot analysis. As
shown in Figure 1A, we found that Eomes protein is upregulated
not only in TCR-stimulated primary CD8+ T cells, but also in stim-
ulated CD4+ T cells. Next we examined the expression of Eomes
in T cells in various helper T cell subsets. As shown in Figure 1B,
Eomes expression was highly induced in differentiated T cells,
especially under Th1 cell conditions. In contrast, expression of
Eomes at both the mRNA level and the protein level was very
low in cells under iTreg and Th17 cell differentiation conditions742 Immunity 34, 741–754, May 27, 2011 ª2011 Elsevier Inc.in which TGF-b was included. Thus, as DNA microarray data
had indicated, Eomes expression was markedly repressed by
TGF-b. In addition, we performed intracellular staining to
examine whether IL-17A+ cells actually do not express Eomes.
As shown in Figure 1C, Eomes expression markedly suppressed
under Th17 cell conditions, especially in IL-17A+ cells.
Then we measured the time course of Eomes protein as well
as Eomes, Tbx21, and Rorc mRNA expression under Th0,
Th0+IL-6, and Th17 cell differentiation conditions (Figure 1D).
As shown in upper panels, Eomes protein was strongly upre-
gulated after 12 hr stimulation and gradually increased under
Th0 cell conditions. In the presence of IL-6 (Th0+IL-6), upregu-
lation of Eomes protein was partly suppressed and severely
repressed under Th17 (TGF-b+IL-6) cell conditions. When
mRNA expression was compared, although Eomes protein
amounts were very low in naive T cells, Eomes mRNA expres-
sion was high in naive T cells (data not shown). Eomes expres-
sion was strongly repressed under Th17 (TGF-b+IL-6) cell
conditions at 6 hr after stimulation, when Rorc induction
started (Figure 1D). Although the mechanism underlying this
discrepancy between protein and mRNA in naive T cells is
not clear at present, Eomes mRNA gradually increased after
6 hr TCR stimulation, and this mRNA increase was strongly
repressed by TGF-b (Th17 cell condition), similar to protein
levels. Rorc expression was kept at low levels under Th0 and
Th0+IL-6 cell conditions. Thus the expression pattern of Eomes
seems to be negatively correlated with that of Rorc. Tbx21,
which is known to suppress Th17 cell differentiation (Lazarevic
et al., 2011; Mukasa et al., 2010), was also depressed in Th17
cell conditions, from 24 hr after stimulation (Figure 1D).
Because induction of Eomes was earlier than that of Tbx21
under Th0 and Th0+IL-6 cell conditions, these data suggest
that Eomes, rather than T-bet, is an early responsive (repres-
sive) gene of TGF-b that correlates with the time course of
RORgt induction.
Eomes Is Suppressed by TGF-b in a Smad-Independent
Manner
To confirm that the Smad signaling pathway is truly not involved
in Eomes repression by TGF-b, we performed real-time PCR and
immunoblot analysis by using Smad2/Smad3+/ T cells. We
used Smad2/Smad3+/ T cells because it was extremely
difficult to obtain large quantities of Smad2/Smad3/ naive
T cells for immunoblot analysis. Consistent with our previous
report, although Foxp3 induction by TGF-b (Figure 1E, Treg cell
condition) was severely impaired in Smad2/Smad3+/
T cells, Rorc induction by TGF-b+IL-6 (Th17 cells) was no
different in these T cells than in WT T cells (Figure 1E). Expect-
edly, under the same conditions, Eomes reduction by TGF-b+
IL-6 was also unaffected (Figure 1E). Similarly, at the protein
level, induction of RORgt and repression of Eomes by TGF-b
were also unaffected by Smad deficiency (Figure 1F). These
results confirmed that Eomes expression is suppressed by
TGF-b in a Smad-independent manner.
The TGF-b-JNK Signaling Pathway Is Involved
in Suppression of Eomes and Induction of Th17 Cells
Next, we investigated the pathway responsible for the repression
of Eomes. It has been known that the non-Smad pathways
Figure 1. Eomes Is Suppressed by TGF-b in a Smad-Independent Manner
(A) Naive CD4+ and CD8+ T cells were cultured for 24 hr with a-CD3 and a-CD28 supplemented with a-IFN-g and a-IL-4. The expression of Eomes protein was
analyzed by immunoblot.
(B) Naive T cells were cultured for 24 hr under the conditions of each Th cell subset. Eomes expression was analyzed by real-time PCR and immunoblot.
(C) Naive T cells were cultured under the Th0 and Th17 cell condition for 3 days. IL-17A and Eomes expressions were analyzed by flow cytometry.
(D) The time course of Eomes mRNA and protein expression, and Tbx21, Rorc mRNA expression in primary T cells. Naive T cells were stimulated under the
conditions of Th0, Th0+IL-6, and Th17 cell differentiation for the indicated periods.
(E) The expression of Eomes, Foxp3, and Rorc mRNA expression in primary T cells from wild-type and LckCre-Smad2/Smad3+/ mice. Naive T cells were
cultured under the conditions of Th0, Treg, Th0+IL-6, and Th17 cells for 48 hr. These mRNA expression were normalized relative to that occurring under Th0 cell
conditions (=1.0).
(F) The expression of Eomes and RORgt protein in T cells from wild-type and LckCre-Smad2/Smad3+/ mice as visualized by immunoblot. Naive T cells were
cultured under the indicated conditions for 24 hr.
All graphs are mean ± SD; n = 3. Representative of two experiments.
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Figure 2. The TGF-b-JNK Signaling Pathway Is Involved in Suppression of Eomes and Induction of Th17 Cells
(A) Expression of Eomes and RorcmRNAs was determined by real-time PCR in primary T cells treated with chemical inhibitors. Naive T cells were cultured with or
without TGF-b supplemented with SP600125 (1 or 10 mM) or PD98059 (10 or 50 mM) or SB203580 (1 or 10 mM) or LY294002 (1 or 5 mM) or Y27632 (1 or 10 mM) or
SB431542 (1 or 10 mM) for 24 hr, and the total RNA was then isolated. An equivalent volume of DMSO was added to cultures only as a control. The relative
expression of Eomes and Rorc mRNA was normalized against that of HPRT.
(B) Naive T cells were cultured under the Th17 cell condition supplemented with SP600125 (10 mM) or SB431542 (10 mM) for 3 days. Inhibitors were added every
24 hr. IL-17A and IFN-g expressions were analyzed by flow cytometry.
(C) IL-17A production in T cells cultured with SP600125. Naive T cells were cultured under the Th17 cell condition supplemented with various quantities of
SP600125 for 3 days and restimulated with a-CD3 for 12 hr at 0.53 106 cells/ml. SP600125 was added every 24 hr. The amount of IL-17A in the supernatants was
measured by ELISA.
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Th17 Cell Induction Requires Suppression of Eomesinclude various branches of MAPkinase (MAPK) pathways, Rho-
like GTPase signaling pathways, and phosphatidylinositol-3-
kinase (PI3K)-AKT pathways (Zhang, 2009). Thus, we examined
the effect of inhibitors for these pathways.
It has previously been reported that JNK2-deficient
(Mapk9/) CD8+ T cells produce higher amounts of IFN-g,
which is associated with increased expression of T-bet and
Eomes (Tao et al., 2007). This suggests that JNK2 negatively
regulates Eomes expression. As shown in Figure 2A, like
TGF-b receptor kinase inhibitor (SB431542), the JNK inhibitor
(SP600125) attenuated the effect of TGF-b on Eomes repres-
sion. Other inhibitors such as MEK inhibitor (PD98059), p38
inhibitor (SB203580), PI3 kinase inhibitor (LY294002), and
ROCK inhibitor (Y27632) did not attenuate the action of TGF-b
on Eomes (Figure 2A). Consistently, Rorc expression was
strongly inhibited by SP600125 in a dose-dependent manner
(Figure 2A).
Then, we investigated the effect of SP600125 on Th17 cell
differentiation of primary T cells. As expected, Th17 cell differen-
tiation was completely abrogated by the addition of SP600125
(Figure 2B). Furthermore, consistent with FACS data, our ELISA
assay revealed that IL-17A production is suppressed by
SP600125 treatment in a dose-dependent manner (Figure 2C).
SP600125 also inhibited the Th17 cell-mediated in vivo disease
model known as EAE (Figure 2D). SP600125-treated mice
were more resistant to EAE than control mice, and less IL-17A
was produced in CD4+ T cells of SP600125-treated mice than
in those of control mice (Figure 2E). Thus, these results suggest
that SP600125 treatment suppresses Th17 cell differentiation
both in vitro and in vivo.
Because SP600125 is not entirely specific for JNK, we inves-
tigated the role of JNK1 and JNK2 by using overexpression
and gene targeting strategies. It has been shown that JNK is
activated in T cells during EAE (Shin et al., 2003). Furthermore,
JNK1-deficient (Mapk8/) mice have been reported to be resis-
tant to EAE (Tran et al., 2006). Previously, it has been reported
that Mapk9/ CD8+ T cells produce higher amounts of IFN-g,
which is associated with increased expression of T-bet and
Eomes (Tao et al., 2007). Thus, JNK1 and JNK2 may negatively
regulate Eomes expression under Th17 cell conditions. As
shown in Figure 2F, JNK1 and JNK2 were highly activated by
TGF-b (Treg and Th17 cell conditions) and partly by IL-6
(Th0+IL-6). Eomes protein amounts were inversely correlated
with JNK activation status. Next, we performed JNK1 and
JNK2 overexpression and gene targeting experiments. As(D) EAE disease course in DMSO-treated and SP600125-treated mice (n = 3 mic
(E) Cytometric data of IL-17A and IFN-g production by CD4+ T cells in spleen and
31 after EAE induction.
(F) The expression of Eomes, JNK, and phosphorylated JNK protein in T cells as vi
for 24 hr.
(G) One day after activation under Th0 and Th0+IL-6 cell polarizing conditions, naiv
(eMIGR), JNK1-IRES-GFP (JNK1), and JNK2-IRES-GFP (JNK2). The cells were a
cells were purified on a FACSAria on day 4. The expression levels of Rorc, Eome
and the data were normalized toHPRT expression.Rorc and EomesmRNA expre
(H) One day after activation under the Th17 cell conditions, naive T cells from W
Luciferase (sh Luciferase), JNK1 (sh JNK1), and JNK2 (sh JNK2). The cells were
purified on a FACSAria on day 4. The expression ofRorc, Il17a, Eomes, Mapk8, an
relative to HPRT expression.
All graphs are mean ± SD; n = 3. Representative of two (A–C, F–H) experiments.shown in Figure 2G, overexpression of JNK1 as well as JNK2
inhibits Eomes expression and enhanced Rorc expression in
the absence of TGF-b (Th0+IL-6) in primary T cells. While target-
ing of JNK1 or JNK2 by shRNA upregulated Eomes expression
and reduced Rorc and Il17a expression in primary T cells (Fig-
ure 2H). Furthermore, when 68-41 cells were stably transformed
with JNK1 and JNK2 shRNAs, TGF-b-mediated Eomes reduc-
tion and induction of Rorc and Il17a was impaired (Figure S1
available online). Collectively, these data suggest that the JNK
signaling pathway is important for Th17 cell development both
in vitro and in vivo.
The JNK Target c-Jun Inhibits Eomes Expression
Next, we examined the effect of c-Jun, a target of JNK, on
Eomes expression. We first measured the amount of Jun
mRNA expression under each Th cell polarizing condition. Jun
mRNA expression was upregulated under Th17 cell polarizing
conditions, but not in Th0 or Th0+IL-6 conditions (Figure 3A).
Next, we investigated the effect of c-Jun on Eomes promoter
activity. The Eomes promoter was cloned as a 2 kb region
upstream from the ATG initiation codon, which is highly
conserved among several species (Mao et al., 2008; Takemoto
et al., 2006). As shown in Figure 3B, c-Jun efficiently suppressed
the activity of the Eomes promoter. Then we examined the role
of c-Jun in Eomes expression by overexpression and gene
targeting of c-Jun in stably infected 68-41 cells. As shown in
Figure 3C, the induction of Eomes by TCR stimulation was
markedly decreased by forced expression of c-Jun at both the
mRNA level and the protein level. Silencing c-Jun expression
by shRNA, however, resulted in enhanced Eomes and reduced
RORgt and Il17a expression (Figure 3D). Taken together, these
results indicate that the TGF-b-JNK-c-Jun signaling pathway
is important for regulating Eomes expression and Th17 cell
induction.
Eomes Suppresses Th17 Cell Differentiation
in Primary T Cells
To determine the role of Eomes in Th17 cell differentiation, we
overexpressed Eomes in primary T cells by retroviral cDNA
transduction. As shown in Figure 4A, overexpression of Eomes
resulted in the repression of IL-17A expression in the transduced
T cells. In contrast, no suppression of IL-17A was observed in
cells infectedwith IRES-GFP control vectors (eMIGR). Reduction
of Th17 cell differentiation by Eomes overexpression was signif-
icant in both Th0+IL-6 and Th17 cell polarizing conditionse per group).
draining lymph nodes from EAE mice treated with or without SP600125 on day
sualized by immunoblot. Naive T cells were cultured under indicated conditions
e T cells fromWTmice were transducedwith retrovirus encoding for IRES-GFP
nalyzed after a total of 4 days in Th0 and Th0+IL-6 cell condition. GFP-positive
s, Makp8 (=Jnk1), andMapk9 (=Jnk2) mRNA were monitored by real-time PCR
ssion were calculated relative to that occurring under Th0 cell conditions (=1.0).
T mice were transduced with retroviral vectors expressing shRNA specific for
analyzed after a total of 4 days in Th17 cell condition. GFP-positive cells were
dMapk9mRNAwasmonitored by real-time PCR and the data were normalized
See also Figure S1.
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Figure 3. c-Jun Inhibits Eomes Expression
(A) The time course of Jun mRNA expression in
primary T cells. Naive T cells were stimulated
under the conditions of Th0, Th0+IL-6, and Th17
cell differentiation for the indicated number of
hours.
(B) 68-41 cells were transfected with Eomes
promoter and b-gal along with various quantities
of c-Jun cDNA. After transfection, 68-41 cells were
cultured with or without PMA + ionomycin for
18 hr, and luciferase activity was measured and
normalized against b-gal activity.
(C) To demonstrate the effect of c-Jun on Eomes
expression by TCR stimulation, we performed
retroviral transduction with retroviral vectors
encoding for IRES-GFP (eMIGR) and Flag-c-Jun-
IRES-GFP (Flag-c-Jun). After infection, GFP-
positive cells were sorted on a FACSAria cell
sorter. Transduced 68-41 cells were cultured for
24 hr with a-CD3 and the total RNA was isolated.
The expression of indicated factors was analyzed
by real-time PCR (bottom) and immunoblot (top).
EomesmRNA expression were calculated relative
to that occurring under nonstimulation (=1.0).
(D) 68-41 cells were stable transformed with
shRNA vector specific to Luciferase and c-Jun.
The expression of the indicated factors was
analyzed by real-time PCR (right) and immunoblot
(left) after 24 hr stimulation with indicated condi-
tions. The expression of mRNA was normalized
relative to HPRT expression. Eomes mRNA ex-
pression was calculated relative to that occurring
under TCR stimulation (=1.0).
All graphs are mean ± SD; n = 3. Representative of
two (A, D) or three (B, C) experiments.
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Th17 Cell Induction Requires Suppression of Eomes(Figure 4A, p < 0.01). Real-time PCR analysis confirmed that the
forced expression of Eomes resulted in a reduction of Il17a and
Rorc transcription (Figure 4B). Alternatively, the induction of
Foxp3 expression by TGF-b was not affected by overexpression
of Eomes (Figure 4C). The reduction in Rorc and Il17a that
resulted from the overexpression of Eomes was partial. For effi-
cient retroviral overexpression, we first had to stimulate naive
T cells for 24 hr prior to retroviral infection. Thus, we probably
observe only partial inhibition because the Th17 cell program
was already initiated before the introduction of Eomes. More
severe suppression of Rorc and Il17a as a result of Eomes over-
expression was observed in the 68-41 T cell line (Figure 4D).
These data suggest that repression of Eomes is necessary for
full Th17 cell differentiation.
Next, we examined the effect of targeting of Eomes expres-
sion by using retroviral vectors expressing shRNA specific for
Eomes (sh Eomes-1, -2). CD4+ primary T cells transduced with
sh Eomes exhibited strong reduction of Eomes expression at
the mRNA and protein levels. Under conditions of Th0+IL-6,
the transduced T cells significantly exhibited upregulated Rorc
and Il17a expression (Figure 4E, p < 0.05). Furthermore,
enhanced RORgt expression was also observed in stable Eomes
shRNA-transformed 68-41 cells (Figure 4F). These data indicate
that repression of Eomes replaced, at least in part, the action of
TGF-b during Th17 cell differentiation. Taken together, the
evidence suggests that Eomes is an essential target of TGF-b
for Th17 cell differentiation.746 Immunity 34, 741–754, May 27, 2011 ª2011 Elsevier Inc.IFN-g and STAT1 Are Not Involved in Suppression
of Th17 Cell Differentiation by Eomes
Next we investigated the molecular mechanism by which Eomes
inhibits Th17 cell development. Consistent with a previous report
(Yang et al., 2008c), overexpression of Eomes enhanced IFN-g
production in primary T cells (Figures 4A and 5A). Thus, one
possibility is that Eomes inhibits Th17 cell differentiation through
the induction of IFN-g, which strongly suppresses Th17 cell
development (Harrington et al., 2005). As shown in Figures 5A
and 5B, however, suppression of IL-17A production by over-
expression of Eomes was still observed in Ifng/ T cells.
Consistently, Il17a and RorcmRNA expression was significantly
suppressed by Eomes even in the absence of IFN-g (Figure 5C,
p < 0.01). In addition, the suppressive function of Eomes for
Th17 cell differentiation was also observed in Stat1/ T cells
(Figure S2). These data indicate that the IFN-g-STAT1 signaling
pathway is not a major mechanism by which Eomes suppresses
Th17 cells.
Eomes Inhibits Rorc and Il17a Promoters via T-box
Binding Elements
To define the mechanism by which Eomes suppresses Rorc and
Il17a expression, we performed a luciferase reporter analysis
with Rorc and Il17a promoter constructs. Overexpression of
Eomes efficiently inhibited PMA plus ionomycin-induced Rorc
and Il17a promoter activity in 68-41 cells in a dose-dependent
manner (Figure 6A). We noticed one and two T-box binding
Immunity
Th17 Cell Induction Requires Suppression of Eomeselements (called T-sites) in Rorc and Il17a proximal promoters,
respectively, each of which read as follows: 50-T(G/C)ACACCT
AGGTGTGAAATT-30. We generated mutants in these T-sites
(Figure S3; Macindoe et al., 2009). These T-sites and their
surrounding regions are highly conserved between rodents and
humans (data not shown), suggesting that this region has an
important function. Overexpression of Eomes efficiently in-
hibited Rorc and Il17a promoter activity, whereas suppression
of the promoter activity by Eomes was severely impaired by
T-site mutations (Figure 6B). The binding of Eomes to these
T-sites was confirmed through ChIP analysis (Figure 6C). These
data suggest that Eomes inhibits the promoter activity of Th17
cell-specific genes by binding to T-box binding elements of
these promoters.
To verify the role of the Eomes T-box domain on Th17 cell
differentiation, we examined a deletion mutant of the T-box
domain (DT-box Eomes) (Figure 6D). DT-box Eomes failed to
inhibit Rorc and Il17a promoter activation (Figure 6E). Similarly,
forced expression of DT-box Eomes failed to suppress Th17
cell differentiation in transduced primary T cells (Figure 6F).
ChIP analysis revealed that DT-box Eomes failed to bind the
Rorc and Il17a promoter (Figure 6G). These results indicate
that interaction between the Eomes T-box region and the T-sites
of Rorc and Il17a promoter is necessary for the suppression of
these genes and Th17 cell differentiation.
DISCUSSION
Despite the well-known role of TGF-b in promoting the differenti-
ationof Th17cells, thesignalingpathwaysusedbyTGF-b to regu-
late this process are largely unknown, because activation of
Smadproteinsdoesnot appear tomediate theprocess (Takimoto
et al., 2010; Yang et al., 2008a). We identified Eomes as a target
of a non-Smad pathway that is necessary for full Th17 cell induc-
tion. The TGF-b-activated JNK-c-Jun signaling pathway strongly
suppressed Eomes expression. Furthermore, the reduction of
Eomes partly replaced TGF-b in the process of RORgt induction.
Thus,TGF-b/JNK/c-Jun/EomesY/RORgt is amechanism
for TGF-b-mediated induction of Th17 cell differentiation.
A recent paper suggests that TGF-b-RhoA-ROCK2 pathway
activation regulates Th17 cell differentiation (Biswas et al.,
2010). Indeed, interfering with ROCK2 function in WT CD4+
T cells caused defective Th17 cell skewing, which supports the
idea that ROCK2 activation by TGF-b plays an intrinsic role in
the differentiation of Th17 cells. ROCK2 has been shown to
phosphorylate IRF4, an essential factor for the induction of
RORgt. Yet, as Biswas et al. (2010) mentioned, reintroduction
of a phosphomimetic form of IRF4 into IRF4-deficient CD4+
T cells failed to generate IL-17-producing cells when these cells
were cultured in the presence of IL-6 alone, suggesting that
TGF-b needs to activate other signaling events in addition to
ROCK2 in order to implement the full Th17 cell differentiation
program. Thus, the non-Smad pathway of TGF-b for Th17 cell
differentiation may not in fact be a single pathway; multiple
TGF-b-non-Smad pathways may be involved in Th17 cell
induction.
We have shown that suppression of IFN-g, IL-2, and IL-4 by
TGF-b is Smad dependent and necessary for full induction of
Th17 cells because these cytokines inhibit Th17 cell differentia-tion (Takimoto et al., 2010). Thus, multiple pathways of TGF-b
signaling are apparently involved in Th17 cell development: the
Smad pathway is necessary for the suppression of anti-Th17
cytokines, the RhoA-ROCK2-IRF4 pathway for RORgt induction,
and the JNK-c-Jun-Eomes pathway for upregulation of RORgt
and IL-17A production (see Graphical Abstract).
The importance of the JNK pathway for Th17 cell development
has been described elsewhere. One group has reported that the
p38 and JNK pathway is important for IL-17A production, based
on experiments with pharmacological inhibitors (Lu et al., 2010).
Another group has reported that the ERK pathway negatively
regulates IL-17A production (Tan and Lam, 2010). Furthermore,
it has been reported that JNK1-deficient (Mapk8/) mice were
resistant to EAE (Tran et al., 2006). Mapk8/ lymphoid cells
were shown to be profoundly defective in IL-17 production.
Fewer Th17 cells were observed in immunized JNK1-deficient
mice. Although JNK1-deficient CD4+ T cells showed defects in
T cell activation and differentiation in vitro (Dong et al., 1998,
2000; Sabapathy et al., 2001), none of these studies address
RORgt induction and Th17 cell differentiation in response to
TGF-b and IL-6 in vitro. In this study, we first demonstrate that
the induction of Rorc and suppression of Eomes by TGF-b is
strongly dependent on JNK1 and JNK2 but not on ERK or PI3
kinase. However, JNK alone cannot explain the full action of
TGF-b because IL-1, which also activates JNK, cannot replace
TGF-b. IL-1 has been shown to promote Th17 cell differentiation,
and thus the JNK-Eomes pathway is probably necessary but not
sufficient for full Th17 cell induction. In any case, we have shown
that SP600125, a JNK inhibitor, ameliorated EAE. Because this
JNK inhibitor is not completely specific to JNK, our data suggest
that the identification of small molecule inhibitors specific for
JNK1 and JNK2 may have therapeutic potential in the treatment
of autoimmune diseases.
The mechanism by which JNK inhibits Eomes expression has
not been clarified. We believe that c-Jun, a substrate of JNK, is
involved in Eomes repression, because overexpression of
c-Jun inhibited Eomes expression and knockdown of c-Jun
abrogated Eomes reduction. Furthermore, c-Jun inhibited
Eomespromoter activity. It hasbeen reported that JNKenhances
the activity of Activator protein-1 (AP-1) (Turjanski et al., 2007),
a transcription factor that consists of a c-Fos-c-Jun heterodimer
(Ashida et al., 2005). The role of c-Fos is not clear at present. Our
preliminary data suggested that c-Fos has an opposite effect on
Eomes and Th17 cells. We found that c-Fos mRNA and protein
expression in Th17 cell polarizing conditions were reduced
compared with those in Th0 cell conditions. In addition, we
showed that overexpression of c-Fos protein enhanced Eomes
promoter and reduced Rorc expression and Th17 cell differenti-
ation (unpublisheddata). Thus, reductionofc-FosbyTGF-bcould
be another mechanism of Th17 cell differentiation. Previously, c-
Fos protein has been shown to repress NF-kB in macrophages
(Koga et al., 2009). The Eomes promoter may be suppressed
by AP-1 (c-Fos-c-Jun heterodimer) but enhanced by ATF2-Jun
heterodimer. The role of c-Fos in Th17 cell differentiation will be
pursued in future studies.
It has been shown in a previous study that the ectopic expres-
sion of Eomes reduces Th17 cell differentiation (Yang et al.,
2008c). Because Eomes is an inducer of IFN-g, it has been
suggested that IFN-g enhanced by Eomes is involved in theImmunity 34, 741–754, May 27, 2011 ª2011 Elsevier Inc. 747
Figure 4. Eomes Suppresses Th17 Cell Differentiation in Primary T Cells
(A) One day after activation under Th0, Th0+IL-6, and Th17 cell polarizing conditions, naive T cells fromWTmice were transduced with retroviral vectors encoding
for IRES-GFP (eMIGR) and Eomes-IRES-GFP (Eomes). The cells were analyzed after a total of 3 or 4 days in Th0 or Th0+IL-6 or Th17 cell-skewed culture. The
panels were gated on GFP-positive cells. The production of IL-17A and IFN-g by the transduced (GFP-positive) cells were examined by intracellular staining. One
representative experiment out of three independent experiments is shown. The bar graph represents the average of IL-17A+CD4+ T cell population in the three
independent experiments. The means ± SD are shown. **p < 0.01.
(B) Relative Il17a, Rorc, andEomesmRNA expression in T cells cultured under the above conditions. GFP-positive cells were purified on a FACSAria on day 3. The
expression levels were monitored by real-time PCR and the data were normalized to HPRT expression.
(C) Relative Foxp3 and Eomes mRNA expression in T cells cultured under iTreg cell differentiation conditions. GFP-positive cells were purified by FACSAria on
day 3. The expression was monitored by real-time PCR and the data were normalized to HPRT expression. Foxp3mRNA expression was calculated relative to
that occurring under Th0 cell conditions (=1.0).
(D) To establish a stable line that constitutively expressed Eomes, we performed retroviral transduction with retroviral vectors encoding for IRES-GFP (eMIGR)
and Eomes-IRES-GFP (Eomes). After infection, GFP-positive cells were sorted on a FACSAria. Transduced 68-41 cells were cultured for 24 hr with a-CD3
supplemented with or without human TGF-b. The expression of the indicated factors was analyzed by real-time PCR and immunoblot.
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Figure 5. IFN-g Is Not Involved in Suppres-
sion of Th17 Cell Differentiation by Eomes
(A) One day after activation under Th17 cell-
polarizing conditions, naive T cells from WT and
Ifng/ mice were transduced with retroviral
vectors encoding for IRES-GFP (eMIGR) and
Eomes-IRES-GFP (Eomes). The cells were
analyzed after a total of 3 or 4 days in Th17 cell-
skewed culture. The panels were gated on
GFP-positive cells. The production of IL-17A and
IFN-g by the transduced (GFP-positive) cells were
examined by intracellular staining. One represen-
tative experiment out of three independent
experiments is shown. The bar graph represents
the average of IL-17A+CD4+ T cell population in
the three independent experiments. The means ±
SD are shown. *p < 0.05, **p < 0.01.
(B) IL-17Aproduction levels inT cells culturedunder
the above conditions. GFP-positive cells were
purified on a FACSAria on day 3 and restimulated
with a-CD3 for 12 hr at 0.5 3 106 cells/ml. The
amount of IL-17A in supernatants was measured
by ELISA. Shown are the means ± SD; n = 3.
Representative of two independent experiments.
(C) Relative Il17a, Rorc, and Eomes mRNA expression levels in T cells cultured under the above conditions. GFP-positive cells were purified on a FACSAria on
day 3. Expression was monitored by real-time PCR and the data were normalized to HPRT expression. The means ± SD of three independent experiments are
shown. **p < 0.01.
See also Figure S2.
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Eomes substantially inhibits RORgt and IL-17A expression
without involvement of IFN-g or STAT1. Instead, as we have
shown, Eomes binds to Rorc and Il17a promoters through the
T-box of Eomes; this interaction suppressed Rorc and Il17a
promoter activity. Recently, Mukasa et al. (2010) have reported
that T-bet binds directly to Rorc promoter. We have also
found that T-bet can inhibit Rorc and Il17a promoter as Eomes
does (data not shown), and it has been reported that
T-bet also suppresses Th17 cell differentiation (Gocke et al.,
2007; Lazarevic et al., 2011; Mathur et al., 2006; Park et al.,
2005; Rangachari et al., 2006). Thus, Eomes and T-bet have
a similar function in Th17 cell suppression. T-bet, however, is
not the downstream target of TGF-b; rather, it is involved in the
late phase of Th17 cell differentiation, as we have shown here
by the observation that repression of T-bet occurred 24 hr after
Th17 cell differentiation. Although we have demonstrated that
Eomes suppresses the promoter activity of Th17 cell-related
genes, the detailed molecular mechanism underlying this
suppression remains to be clarified.
Eomes and T-bet both enhance Ifng promoter activity and
suppress Rorc and Il17a promoter activity. It is not clear how
one transcription factor possesses opposing functions depend-
ing on the target genes. Th17 cells have been shown to have
permissiveH3K4methylationbut no repressiveH3K27me3modi-(E) One day after activation under the Th0+IL-6 cell condition, naive T cells from W
Luciferase (sh Luciferase) and Eomes (sh Eomes). The cells were analyzed after
a FACSAria on day 3. The expression levels ofRorc, Il17a, andEomesmRNAwere
The means ± SD of three independent experiments are shown. *p < 0.05, **p < 0
(F) To establish a stable line in which Eomes expression was downregulated, w
specific for Luciferase (sh Luciferase) and Eomes (sh Eomes). Infected 68-41 cell
indicated factors was analyzed by real-time PCR and immunoblot. The relative e
All graphs (B–D, F) are mean ± SD; n = 3. Representative of three (B–D) or two (Ffications at the promoters of Il17a and Il17f (Wei et al., 2009).
Furthermore, Th17 cells are also reported to have increased
permissive H3 acetylation at the Il17a and Il17f promoters as
well as several conserved noncoding sequences (CNSs) in the
Il17a-Il17f locus (Akimzhanov et al., 2007). A previous report has
shown that T-box proteins have a conserved ability to physically
and functionally interact with H3K27-demethylase and H3K4-
methyltransferase complexes through the T-box DNA binding
domain (Miller et al., 2008). Thus, it is plausible that Eomes
controls repressive epigenetic processes (e.g., recruitment of
HDAC, H3K4-demethylase, and H3K27-methyltransferase).
In conclusion, we have demonstrated that the repression of
Eomes by the TGF-b-JNK-c-Jun signaling pathway is an impor-
tant mechanism for the full induction of Th17 cell differentiation.
Eomes as well as T-bet could be therapeutic targets in the
treatment of autoimmune disease and allergy.
EXPERIMENTAL PROCEDURES
Mice and Cell Lines
C57BL/6 mice were purchased from CLEA Japan, Inc. (Tokyo, Japan).
Smad2/Smad3+/ mice have been described previously (Takimoto et al.,
2010). Ifng/ andStat1/mice have also been described previously (Hanada
et al., 2003). All mice were between the ages of 6 and 12 weeks during the
experiments. Mice were kept in specific-pathogen-free facilities at Keio
University. All experiments with mice were approved by and performedT mice were transduced with retroviral vectors expressing shRNA specific for
a total of 3 days in Th0+IL-6 cell condition. GFP-positive cells were purified on
monitored by real-time PCR and the datawere normalized toHPRT expression.
.01. The expression level of Eomes protein was analyzed by immunoblot.
e performed retroviral transduction with a retroviral vector expressing shRNA
s were cultured for 24 hr under the indicated conditions. The expression of the
xpression of these factors was normalized against that of HPRT.
) experiments.
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Figure 6. Eomes Inhibits Rorc and Il17a Promoter via T-Box Binding Elements
(A) 68-41 cells were transfected with Rorc or Il17a promoter and b-gal along with various quantities of Eomes cDNA. After transfection, 68-41 cells were cultured
with or without PMA + ionomycin for 18 hr, after which luciferase activity was measured and normalized against b-gal activity.
(B) 68-41 cells were transfected with indicated reporter plasmids, Eomes cDNA, and b-gal. After transfection, 68-41 cells were cultured with or without PMA +
ionomycin for 18 hr, after which luciferase activity was measured and normalized against b-gal activity.
(C) TheChIP assay of Eomes on theRorc and Il17a promoter region (proximal) were performed in 68-41 cells transducedwith retroviral vectors encoding for IRES-
GFP (eMIGR) and Eomes-IRES-GFP (Eomes). Cell lysates were immunoprecipitatedwith a-Eomes or control IgG. Accessibility of Eomeswas determined by real-
time PCR and was normalized by the input.
(D) Left: Diagram of WT Eomes and T-box domain deleted mutant (DT-box Eomes). Right: The protein expression of WT Eomes and DT-box Eomes as visualized
by immunoblot.
(E) 68-41 cells were transfected withRorc or Il17a promoter and b-gal along withWT Eomes orDT-box Eomes cDNA. After transfection, 68-41 cells were cultured
with or without PMA + ionomycin for 18 hr, after which luciferase activity was measured and normalized against b-gal activity.
(F) One day after activation under Th0, Th0+IL-6, and Th17 cell polarizing conditions, naive T cells fromWTmice were transduced with retroviral vectors encoding
for IRES-GFP (eMIGR), Eomes-IRES-GFP (Eomes), and DT-box Eomes-IRES-GFP (DT-box Eomes). The cells were analyzed after a total of 3 days in Th0 or
Th0+IL-6 or Th17 cell-skewed culture. The panels were gated on GFP-positive cells. The production of IL-17A and IFN-g by the transduced (GFP-positive) cells
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Th17 Cell Induction Requires Suppression of Eomesaccording to the guidelines of the Animal Ethics Committee of Keio University.
T cell line 68-41 cells were provided by M. Kubo and have been described
previously (Kubo et al., 1994).
Plasmids
PCR was performed to generate murine Rorc and murine Eomes promoter
plasmids with mouse genomic DNA as a template. In the case of murine
Rorc promoter, an approximately 0.67 kb fragment corresponding to nucleo-
tides from 533 to +136 relative to the determined transcriptional starting site
of Rorc gene was subcloned into pGV-basic 2 vector (TOYOINKI). In the case
of murine Eomes promoter, an approximately 2 kb fragment corresponding to
nucleotides from 1671 to +320 relative to the determined transcriptional
starting site of Eomes gene was subcloned into pGL4.27 vector (Promega).
Themurine Il17a promoter plasmids have been described previously (Ichiyama
et al., 2008). The point mutations in a putative T-box binding site were intro-
duced through PCR with the following primers: Rorc promoter, 50-CGCC
CCTCTTTGCCTGCCCCAGACCC-30 and 50-GGGTCTGGGGCAGGCAAAG
AGGGGCG-30; Il17a promoter, 50-CTGAATCGGGGCAAAGCATCTCTGTTC
AGC-30 and 50-GCTGAACAGAGATGCTTTGCCCCGATTCAG-30; 50-GCACTA
CTCTTCATCCGGTTCTTTCGAGGC-30 and 50-GCCTCGAAAGAACCGGAT
GAAGAGTAGTGC-30.
eMIGR/Eomeswas provided by K. Yasutomo and has been described previ-
ously (Pearce et al., 2003). The deletion fragments of Eomes were amplified by
PCR to generate a T-box-deleted mutant of eMIGR/Eomes (DT-box Eomes).
The Eomes fragment from eMIGR/Eomes was inserted into the pcDNA3.1
vector (Invitrogen) to generate pcDNA3.1/Eomes. Murine c-Jun cDNA was
amplified by RT-PCR. The cDNA was inserted into a eMIGR/FLAG(x2) vector
and pCMV vector (Takaesu et al., 2000) to generate eMIGR/FLAG(x2)-c-Jun
and pCMV/c-Jun, respectively.
Retroviral shRNA Constructs
shRNA target sequences were selected based on the BLOCK-iT RNAi
Designer (Invitrogen). The following oligos were amplified with the XhoI and
EcoRI amplification primers and subcloned into the MSCV-LMP vector
(Open Biosystems) according to the manufacturer’s instructions: sh Eomes-1,
50-TGCTGTTGACAGTGAGCGCGGGCAATAAGATGTACGTTCATAGTGAAG
CCACAGATGTATGAACGTACATCTTATTGCCCTTGCCTACTGCCTCGGA-30;
sh Eomes-2, 50-TGCTGTTGACAGTGAGCGCGCTAGACATCGGTTCTTATGA
TAGTGAAGCCACAGATGTATCATAAGAACCGATGTCTAGCTTGCCTACTGC
CTCGGA-30, where the underlined sequences are specific for the murine
Eomes; sh JNK1, 50-TGCTGTTGACAGTGAGCGCGGAATAGTGTGTGCAG
CTTATTAGTGAAGCCACAGATGTAATAAGCTGCACACACTATTCCTTGCCTA
CTGCCTCGGA-30; sh JNK2, 50-TGCTGTTGACAGTGAGCGCGCCTTGCGC
CACCCGTATATTTAGTGAAGCCACAGATGTAAATATACGGGTGGCGCAAGGC
TTGCCTACTGCCTCGGA-30, where the underlined sequences are specific for the
murine JNK1 or JNK2; sh c-Jun, 50-TGCTGTTGACAGTGAGCGCGCGCACG
CTCCTAAACAAACTTAGTGAAGCCACAGATGTAAGTTTGTTTAGGAGCGTGCGC
TTGCCTACTGCCTCGGA-30, where the underlined sequences are specific for
the murine c-Jun.
The following plasmid expressing shRNA against the Luciferase gene was
used as a control: sh Luciferase, 50-TGCTGTTGACAGTGAGCGCCGGT
GGCTCCCGCTGAATTGGATAGTGAAGCCACAGATGTATCCAATTCAGCGG
GAGCCACCTTGCCTACTGCCTCGGA-30.
Naive T Cell Preparation and Differentiation
Single-cell suspensions frommouse spleens and lymph nodeswere negatively
depleted by first staining with a-B220-biotin, a-CD11b-biotin, a-CD11c-biotin,
a-Ter119-biotin, a-DX5-biotin, a-CD8a-biotin, a-Gra1-biotin, and a-CD25-was examined by intracellular staining. One representative experiment out of thre
IL-17A+CD4+ T cell population in the three independent experiments. The means
(G) A ChIP assay of Eomes on the Rorc and Il17a promoter region (proximal an
encoding for IRES-GFP (eMIGR), Eomes-IRES-GFP (Eomes), and DT-box Eom
a-Eomes or control IgG. Accessibility of Eomes was determined by real-time PC
control IgG immunoprecipitates are shown.
All graphs (A–C, E, G) are mean ± SD; n = 3. Representative of three (A, B, E) orbiotin (all from eBioscience) at a 1:125 dilution for 20 min on ice, then incu-
bating with streptoavidin-conjugated magnetic microbeads (Miltenyi Biotech)
at a 1:20 dilution for 20 min on ice. The depleted fraction was stained with
a-CD62L-FITC, a-CD25-PE, a-CD4-PerCP, and a-CD44-APC. Cell sorting
was performed with a FACSAria cell sorter (Becton Dickinson) to obtain a
pure population of primary CD4+CD25CD62LhiCD44lo T cells (typically >98%
purity). The CD4+CD25CD62LhiCD44lo T cells (1 3 106 cells/well) were
cultured at 37C (5% CO2) in RPMI-1640 (Invitrogen Life Technologies). The
medium was supplemented with 10% FCS, 2 mM L-glutamine, 100 U/ml
penicillin, 100 mg/ml streptomycin, and 50 mM 2-mercaptoethanol. The cells
were stimulated with the plate-bound a-CD3 (1 mg/ml, clone 145-2C11) and
the soluble a-CD28 (0.5 mg/ml, eBioscience). For Th0 cell differentiation, the
cells were treated with 5 mg/ml a-IFN-g (R4-6A2) and 5 mg/ml a-IL-4 (11B11).
For Th1 cell differentiation, the cells were treated with 10 ng/ml mIL-12p70
(R&D Systems) and 5 mg/ml a-IL-4. For Th2 cell differentiation, the cells were
treated with 10 ng/ml mIL-4 (PeproTech) and 5 mg/ml a-IFN-g. For iTreg cell
differentiation, the cells were treated with 2 ng/ml human TGF-b (R&D
Systems), 5 mg/ml a-IFN-g, and 5 mg/ml a-IL-4. For Th0+IL-6 cell differentia-
tion, the cells were treated with 20 ng/ml human IL-6 (R&D Systems), 5 mg/ml
a-IFN-g, 5 mg/ml a-IL-4, and 5 mg/ml a-TGF-b (1D11). For Th17 cell differenti-
ation, the cells were treated with 1 ng/ml human TGF-b, 20 ng/ml human IL-6,
5 mg/ml a-IFN-g, and 5 mg/ml a-IL-4. In the case of Stat1/ experiment,
a-IFN-g and a-IL-4 were removed from culture medium.
Retroviral Transduction
Naive CD4+CD25CD62LhiCD44lo T cells were plated and subjected to the
various Th cell differentiation conditions described above, starting on day 0.
On day 1, fresh retrovirus supernatant was added and the cells were spun at
2500 rpm for 2 hr at 35C. After spin infection, the cells were cultured in the
appropriate Thcell differentiationmediaandharvestedonday3or 4 for intracel-
lular cytokine staining and real-time PCR analysis. Cell sorting was performed
with a FACSAria cell sorter (Becton Dickinson) to obtain GFP-positive cells.
Flow Cytometry
For intracellular cytokine staining, cells were stimulated for 5 hr in complete
medium with phorbol 12-myristate 13-acetate (50 ng/ml) and ionomycin
(500 ng/ml; both from Sigma-Aldrich) in the presence of brefeldin A
(eBioscience). Surface staining was then performed in the presence of
Fc-blocking Abs (2.4G2), followed by intracellular staining for cytokines with
the Fixation and Permiabilization kit (eBioscience) according to the manufac-
turer’s instructions. All Abs were obtained from eBioscience. Data were
acquired through a BD FACSAria or BD FACS Canto II and were analyzed
with FlowJo software (Tree Star, Ashland, OR).
Luciferase Assay
Both the process of transfection into 68-41 cells and the luciferase assay have
been described previously (Ichiyama et al., 2009). In brief, 68-41 cells were
seeded on 6-well plates (1 3 106 cells/well) and transfected with various
amounts of expression vector with Fugene HD reagent. After transfection,
68-41 cells were cultured for 24 hr, then restimulated with or without PMA
plus ionomycin for 18 hr. All cells were harvested with 50 ml of lysis buffer.
The luciferase assay was performed with a luciferase substrate kit (Promega),
and luciferase activity was read with a Packard luminometer and normalized to
an internal control, namely, b-galactosidase (b-gal).
Immunoblot Analysis
Immunoblot was performed as described previously (Ichiyama et al., 2009). In
brief, cells were washed, lysed in sample buffer, and boiled. Whole cell lysatese independent experiments is shown. The bar graph represents the average of
± SD are shown. **p < 0.01.
d distal) were performed in primary T cells transduced with retroviral vectors
es-IRES-GFP (DT-box Eomes). Cell lysates were immunoprecipitated with
R. The ratios of the levels of PCR in a-Eomes immunoprecipitates to that in
two (C, G) experiments. See also Figure S3.
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a polyvinylidene difluoride membrane (Millipore). The membrane was blocked
and probed with the following primary Abs: a-b-actin (A2066; Sigma-Aldrich),
a-Smad2/3 (610843, BD Biosciences PharMingen), a-Eomes (ab23345,
Abcam), a-RORc (14-6981-80, eBioscience or 14-6988-80 eBioscience),
a-c-Jun (sc-45, Santa Cruz), a-JNK (#9252S, Cell Signaling), a-phospho-
JNK (#9255S, Cell Signaling), and a-FLAG (F3165, Sigma-Aldrich). The
membrane was then probed with appropriate secondary Abs conjugated to
HRP and visualized with the Chemi-Lumi One L Immunoblot detection
reagents (Nacalai Tesque) according to the manufacturer’s instructions.
b-actin was used as a loading control.
ELISA and RT-PCR
Supernatants were collected after the indicated periods of cell culture and
were analyzed for IL-17A with an ELISA kit (eBioscience) according to the
manufacturer’s instructions.
The cells were lysed in RNAiso extraction reagent (Takara) which allowed
RNA extraction. RT-PCR was carried out with the one-step RT-PCR kit
(Applied Biosystems). Real-time PCR was performed on cDNA samples with
the SYBR Green system (Applied Biosystems). The relative quantitation value
is expressed as 2DCt, where DCt is the difference between the mean Ct value
of triplicates of the sample and that of the endogenous HPRT control. The
primer sequences were as follows: HPRT, 50-TGAAGAGCTACTGTAATGATC
AGTCAAC-30 and 50-AGCAAGCTTGCAACCTTAACCA-30; Rorc, 50-CCGC
TGAGAGGGCTTCAC-30 and 50-TGCAGGAGTAGGCCACATTACA-30; Il17a,
50-CACCTCACACGAGGCACAAG-30 and 50-CAGCAACAGCATCAGAGAC
ACA-30; Foxp3, 50-CCCAGGAAAGACAGCAACCTT-30 and 50-TTCTCACAACC
AGGCCACTTG-30; Eomes, 50-GTGACGGCCTACCAAAACAC-30 and 50-GAC
CTCCAGGGACAATCTGA-30; Tbx21, 50-GGTGTCTGGGAAGCTGAGAG-30
and 50-GAAGGACAGGAATGGGAACA-30; Jun, 50-TGGGCACATCACCACTA
CAC-30 and 50-GACACTGGGAAGCGTGTTCT-30; Mapk8, 50-GTGCTTTT
CCCAGCTGACTC-30 and 50-ATGTATGGGTGCTGGAGAGC-30; and Mapk9,
50-GGGGTAAAAGACCAGCCTTC-30 and 50-CTGTTGAGGCATCGAGACTG-30.
Chromatin Immunoprecipitation Assay
The chromatin immunoprecipitation (ChIP) assay was performed as previously
described (Koga et al., 2009) with a ChIP assay kit (Upstate Biotechnology). In
brief, primary T cells and 68-41 cells were fixed with 1% formaldehyde at 37C
for 10min and then suspended in an SDS lysis buffer. After sonicationwith 30 s
pulses 15 times from a Bioruptor sonicator (Cosmo Bio.), samples were incu-
bated with 2.5 mg of medium containing antibodies or control IgG overnight at
4C. After the addition of salmon sperm DNA and ProteinA-Agarose Slurry, the
immunoprecipitates were sequentially washed once each with a low-salt
buffer, a high-salt buffer, and a LiCl buffer and twice with a TE buffer. The
DNA-protein complex was eluted by heating at 65C for 6 hr. Proteins were
then digested with proteinase K, and RNA was removed by the addition of
10 mg of RNase A. DNA was recovered with the QIAquick PCR Purification
Kit (QIAGEN) and then subjected to real-time PCR analysis addressing the
Rorc and Il17a promoter regions. Real-time PCR was performed with the
following primers: Rorc promoter, proximal 50-AGGAATTTGGGTGTGGT
GAG-30 and 50-ATCAGGGGTAGGGATGTTCC-30, distal 50-GACAGTGAAGGAG
GGACAGG-30 and 50-CCTAGAGAGGGAGCCCTTGG-30; and Il17a promoter,
proximal 50-GGTGGTTCTGTGCTGACCTC-30 and 50-TCGTGTGAGGTGGAT
GAAGA-30, distal 50-CTTCCAGGTCTTTCTGCCTGT-30 and 50-TGCTTGCT
GTGAATGTGTGAG-30.
Experimental Autoimmune Encephalomyelitis
Myelin oligodendrocyte glycoprotein (MOG) peptide 35-55 (MEVGWYRS
PFSRVVHLYRNGK) (BEX) was used to induce experimental autoimmune
encephalomyelitis (EAE) in mice (Matsumura et al., 2007). Mice were injected
s.c. with 200 mg of MOG peptide in 100 ml of PBS emulsified in 100 ml CFA that
was further enriched with 5 mg/mlMycobacterium tuberculosis (H37Ra; Difco
BD Biosciences). In addition, 500 ng pertussis toxin (Calbiochem) was injected
i.p. on days 0 and 2. The JNK inhibitor (SP600125; 0.5 mg/kg) (Calbiochem)
was injected i.p. into WT mice 2 days after immunization with MOG peptide,
and injection was repeated every other day for 11 days. Mice that received
DMSO solution only were used as controls. Paralysis was evaluated according752 Immunity 34, 741–754, May 27, 2011 ª2011 Elsevier Inc.to the following scale: 0, no disease; 1, tail limpness; 2, hind limb weakness; 3,
hind limb paralysis; 4, fore limb weakness; 5, quadriplegia; 6, death.
Statistical Analysis
The Student’s paired two-tailed t test was used. Values of p < 0.05 were
considered significant. All error bars shown in this article represent standard
deviations.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and can be found with this
article online at doi:10.1016/j.immuni.2011.02.021.
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